CanadaBis Capital Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

CanadaBis Capital has been growing earnings at an average annual rate of 69.8%, while the Pharmaceuticals industry saw earnings growing at 46% annually. Revenues have been growing at an average rate of 49.7% per year. CanadaBis Capital's return on equity is 25.9%, and it has net margins of 11.6%.

Anahtar bilgiler

69.8%

Kazanç büyüme oranı

71.9%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi23.1%
Gelir büyüme oranı49.7%
Özkaynak getirisi25.9%
Net Marj11.6%
Son Kazanç Güncellemesi30 Apr 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) Low P/E

Oct 13
Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) Low P/E

We Think CanadaBis Capital (CVE:CANB) Is Taking Some Risk With Its Debt

Aug 19
We Think CanadaBis Capital (CVE:CANB) Is Taking Some Risk With Its Debt

Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) 29% Share Price Plunge

Jul 14
Why Investors Shouldn't Be Surprised By CanadaBis Capital Inc.'s (CVE:CANB) 29% Share Price Plunge

CanadaBis Capital (CVE:CANB) Has A Pretty Healthy Balance Sheet

May 09
CanadaBis Capital (CVE:CANB) Has A Pretty Healthy Balance Sheet

Earnings Working Against CanadaBis Capital Inc.'s (CVE:CANB) Share Price Following 48% Dive

Apr 02
Earnings Working Against CanadaBis Capital Inc.'s (CVE:CANB) Share Price Following 48% Dive

If EPS Growth Is Important To You, CanadaBis Capital (CVE:CANB) Presents An Opportunity

Feb 12
If EPS Growth Is Important To You, CanadaBis Capital (CVE:CANB) Presents An Opportunity

Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

Dec 01
Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

CanadaBis Capital (CVE:CANB) Seems To Use Debt Quite Sensibly

Jul 17
CanadaBis Capital (CVE:CANB) Seems To Use Debt Quite Sensibly

CanadaBis Capital Inc.'s (CVE:CANB) Shares Climb 70% But Its Business Is Yet to Catch Up

Apr 17
CanadaBis Capital Inc.'s (CVE:CANB) Shares Climb 70% But Its Business Is Yet to Catch Up

Auditors Have Doubts About CanadaBis Capital (CVE:CANB)

Dec 01
Auditors Have Doubts About CanadaBis Capital (CVE:CANB)

Is CanadaBis Capital (CVE:CANB) A Risky Investment?

Aug 13
Is CanadaBis Capital (CVE:CANB) A Risky Investment?

Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

Apr 30
Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

Is CanadaBis Capital (CVE:CANB) Using Debt Sensibly?

Jan 13
Is CanadaBis Capital (CVE:CANB) Using Debt Sensibly?

Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

Apr 07
Is CanadaBis Capital (CVE:CANB) Using Too Much Debt?

Have Insiders Been Selling CanadaBis Capital Inc. (CVE:CANB) Shares This Year?

Feb 14
Have Insiders Been Selling CanadaBis Capital Inc. (CVE:CANB) Shares This Year?

Here's Why CanadaBis Capital (CVE:CANB) Can Afford Some Debt

Dec 23
Here's Why CanadaBis Capital (CVE:CANB) Can Afford Some Debt

Gelir ve Gider Dağılımı

CanadaBis Capital nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

TSXV:CANB Gelir, gider ve kazançlar (CAD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Apr 2419270
31 Jan 2421370
31 Oct 2323470
31 Jul 2322470
30 Apr 2322460
31 Jan 2318350
31 Oct 2215250
31 Jul 2212140
30 Apr 229-150
31 Jan 228-150
31 Oct 218-250
31 Jul 217-340
30 Apr 219-240
31 Jan 217-240
31 Oct 206-340
31 Jul 204-560
30 Apr 201-1080
31 Jan 200-1380
31 Oct 190-1270
31 Jul 190-950
30 Apr 190-510
31 Jan 190-110
31 Oct 180000
31 Jul 180000

Kaliteli Kazançlar: CANB has a high level of non-cash earnings.

Büyüyen Kar Marjı: CANB's current net profit margins (11.6%) are lower than last year (17%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CANB has become profitable over the past 5 years, growing earnings by 69.8% per year.

Büyüme Hızlandırma: CANB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: CANB had negative earnings growth (-40.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-40.8%).


Özkaynak Getirisi

Yüksek ROE: CANB's Return on Equity (25.9%) is considered high.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin